Temporal Trends in the Burden of Chronic Kidney Disease in the United States
Overview
Nephrology
Authors
Affiliations
Purpose Of Review: The public health importance of chronic kidney disease (CKD) has only recently come to be appreciated and careful examination of temporal trends is warranted. The purpose of the present review was to examine existing research on temporal trends for CKD and treated end-stage renal disease (ESRD) in the United States.
Recent Findings: When the broadly representative National Health and Nutrition Examination Survey (NHANES) datasets were compared in 1988-1994 and 1999-2002, a pronounced increase in the prevalence of abnormally low glomerular filtration rate was observed when serum creatinine was used to estimate glomerular filtration rate. In contrast, glomerular filtration rate findings were almost identical when cystatin C levels were examined. Thus, although the community-wide burden of CKD is already high, uncertainty exists as to the growth rate of this problem. For treated ESRD a dramatic increase in incidence rate occurred in the 1980s and 1990s. Changing burdens of standard risk factors for CKD do not readily explain increased rates of treated ESRD, suggesting that selection criteria for dialysis and transplant programs may underlie these secular trends. If the hypothesis that nonbiological factors are major determinants of rates of treated ESRD is valid, the latter may be a poor surrogate for true ESRD and for understanding its causes and rates of progression.
Summary: Given its prevalence and prognostic implications, it makes intuitive sense to monitor the burden of CKD over time; the validity of the tools used to generate an answer, however, is at least as important as the direction of the answer.
Trends in the prevalence of Chronic Kidney Disease in the United States, 1999-2018.
Zhuang M, Lv X, Zhu Y, Zheng N, Zhan Y Front Med (Lausanne). 2025; 11:1499225.
PMID: 39882533 PMC: 11774909. DOI: 10.3389/fmed.2024.1499225.
Marx N, Wanner C, Jankowski J, Marz W, Krane V, Genser B Clin Kidney J. 2023; 16(10):1612-1621.
PMID: 37779851 PMC: 10539202. DOI: 10.1093/ckj/sfad029.
Lu J, Lee P, Ierino F, MacIsaac R, Ekinci E, ONeal D J Diabetes Sci Technol. 2023; 18(6):1500-1508.
PMID: 37162092 PMC: 11531035. DOI: 10.1177/19322968231174040.
PGC1 plays a pivotal role in renal fibrosis via regulation of fatty acid metabolism in renal tissue.
Zhang R, Zeng J, Deng Z, Yin G, Wang L, Tan J Zhong Nan Da Xue Xue Bao Yi Xue Ban. 2022; 47(6):786-793.
PMID: 35837779 PMC: 10930027. DOI: 10.11817/j.issn.1672-7347.2022.200953.
Vinnakota S, Scott C, Rodeheffer R, Chen H Mayo Clin Proc. 2019; 94(11):2189-2198.
PMID: 31668448 PMC: 6959123. DOI: 10.1016/j.mayocp.2019.03.033.